Literature DB >> 30570878

Survival of patients with primary osteosarcoma and lung metastases.

Wei Li1, Shiquan Zhang.   

Abstract

PURPOSE: To investigate the survival of patients with primary osteosarcoma and lung metastases.
METHODS: Clinical data of 128 patients with primary osteosarcoma and lung metastases who were admitted to Shenzhen Second People's Hospital from January 2013 to January 2015, were enrolled and retrospectively analyzed. Follow-up lasted for 3 years and after follow-up, patients were divided into survival group (n=54) and death group (n=74) according to their survival status. Univariate and logistic multivariate analyses were conducted on related factors contributing to death in patients with primary osteosarcoma and lung metastases.
RESULTS: At the end of follow-up, there were 74 deaths (death group) and 54 survivors (survival group). Among all 128 patients, the 6-month, 1-year, 2-year and 3-year survival rates were 96.87, 92.96, 61.71 and 42.18%, respectively . Univariate analysis showed that tumor diameter, histological subtype, visceral pleural involvement, the number of lung metastatic lesions, the outcome after chemotherapy for the primary tumor, and therapy for lung metastasis were closely associated with death in patients with primary osteosarcoma and lung metastases (p<0.05). Multivariate logistic regression analysis showed that chondrocytes, multiple lung metastatic lesions, poor outcome after chemotherapy for primary tumor, and no surgery-combined treatment for lung metastasis were risk factors contributing to death in patients with primary osteosarcoma and lung metastases (p<0.05).
CONCLUSION: Risk factors contributing to death in patients with primary osteosarcoma and lung metastases include chondrocytes, multiple lung metastatic lesions, poor outcome after chemotherapy for primary tumor, and no surgery-combined treatment for lung metastasis. Surgical resection and preoperative adjuvant chemotherapy can effectively improve the patient survival.

Entities:  

Mesh:

Year:  2018        PMID: 30570878

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  12 in total

1.  MicroRNA-449b-5p Suppresses Proliferation, Migration, and Invasion of Osteosarcoma by Targeting c-Met.

Authors:  Qian Li; Changliang Lu; Jingye Wang; Min Gao; Wei Gao
Journal:  Med Sci Monit       Date:  2019-08-19

2.  Identification and Functional Analysis of EPOR+ Tumor-Associated Macrophages in Human Osteosarcoma Lung Metastasis.

Authors:  Yanxing Li; Ming Li; Rong Wei; Junlong Wu
Journal:  J Immunol Res       Date:  2020-08-18       Impact factor: 4.818

3.  Identification of Lysosome-Associated Protein Transmembrane-4 as a Novel Therapeutic Target for Osteosarcoma Treatment.

Authors:  Zhe-Xiang Wang; Meng-Yang Guo; Jing Ren; Gui-Shi Li; Xu-Guo Sun
Journal:  Orthop Surg       Date:  2020-06-18       Impact factor: 2.071

4.  LncRNA SNHG16 promotes epithelial-mesenchymal transition by upregulating ITGA6 through miR-488 inhibition in osteosarcoma.

Authors:  Jie Bu; Ru Guo; Xue-Zheng Xu; Yi Luo; Jian-Fan Liu
Journal:  J Bone Oncol       Date:  2021-01-19       Impact factor: 4.072

5.  [Progress in Surgery for Pulmonary Metastases].

Authors:  Bo Liu; Hui Xia
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-09-20

6.  Mesenchymal stromal cells mediated delivery of photoactive nanoparticles inhibits osteosarcoma growth in vitro and in a murine in vivo ectopic model.

Authors:  Stefania Lenna; Chiara Bellotti; Serena Duchi; Elisa Martella; Marta Columbaro; Barbara Dozza; Marco Ballestri; Andrea Guerrini; Giovanna Sotgiu; Tommaso Frisoni; Luca Cevolani; Greta Varchi; Mauro Ferrari; Davide Maria Donati; Enrico Lucarelli
Journal:  J Exp Clin Cancer Res       Date:  2020-02-22

7.  Identification of Kinesin Family Member 2A (KIF2A) as a Promising Therapeutic Target for Osteosarcoma.

Authors:  Zhe-Xiang Wang; Shao-Chun Ren; Zi-Song Chang; Jing Ren
Journal:  Biomed Res Int       Date:  2020-10-29       Impact factor: 3.411

8.  Thiostrepton and miR-216b synergistically promote osteosarcoma cell cytotoxicity and apoptosis by targeting FoxM1.

Authors:  Xiaobing Cai; Wenyu Xiao; Juexin Shen; Hui Lian; Yi Lu; Xianmiao Liu; Jisheng Gu
Journal:  Oncol Lett       Date:  2020-10-29       Impact factor: 2.967

Review 9.  Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers.

Authors:  Guillaume Anthony Odri; Joëlle Tchicaya-Bouanga; Diane Ji Yun Yoon; Dominique Modrowski
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

10.  Long non-coding RNA HCG11 enhances osteosarcoma phenotypes by sponging miR-1245b-5p that directly inhibits plakophilin 2.

Authors:  Hao Yan; Yong Zhou; Zhujiang Chen; Xiaokang Yan; Ling Zhu
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.